Company Encyclopedia
View More
name
IMMUNEONCO-B
01541.HK
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL. In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors.
1.267 T
01541.HKMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking33/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-53.34%E
    • Profit Margin-246.42%E
    • Gross Margin100.00%A
  • Growth ScoreA
    • Revenue YoY1587.47%A
    • Net Profit YoY19.03%B
    • Total Assets YoY5.69%B
    • Net Assets YoY-9.40%D
  • Cash ScoreB
    • Cash Flow Margin-40.58%D
    • OCF YoY1587.47%A
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreB
    • Gearing Ratio30.78%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Immuneonco Biopharmaceuticals Shanghai Inc says CEO purchases 50,000 H shares at average price of HK$6.6258 each

    Immuneonco Biopharmaceuticals Shanghai Inc says CEO purchases 50,000 H shares at average price of HK$6.6258 each

    marketscreener·
    HK
    01541
    +2.31%
    marketscreener·
    HK
    01541
    +2.31%

    Immuneonco Biopharmaceuticals Wins CDE Approval for Phase III Trial of IMM0306 in Follicular Lymphoma

    Immuneonco Biopharmaceuticals has received approval from the Center for Drug Evaluation for a Phase III trial of IMM0306 in combination with lenalidomide for treating relapsed/refractory follicular lymphoma. IMM0306 is a bispecific molecule targeting CD47 and CD20, marking a significant step in innovative therapy development. The company holds global intellectual property and commercial rights to IMM0306.

    Reuters·
    HK
    01541
    +2.31%
    Reuters·
    HK
    01541
    +2.31%

    IMMUNEONCO-B: The first patient has been dosed in the Phase IB/II clinical trial of IMM2510 in combination with IMM01

    IMMUNEONCO-B announced that the Phase IB/II clinical trial of IMM2510 in combination with IMM01 has successfully completed the first patient dosing, marking an important advancement in the field of cancer immunotherapy. IMM2510 is a bispecific molecule targeting VEGF and PD-L1, designed to inhibit tumor angiogenesis and enhance immune response. The company has signed a cooperation agreement with Axion Bio, Inc. to obtain the commercialization rights for IMM2510 in the Greater China region. The core product IMM01 is China's first SIRPα-Fc fusion protein to enter clinical stages, featuring a dual mechanism for activating macrophages

    Zhitong·
    HK
    01541
    +2.31%
    Zhitong·
    HK
    01541
    +2.31%

    IMMUNEONCO-B has completed the issuance of a total of 24.2 million placement shares

    IMMUNEONCO-B has completed the issuance of 24.2 million placement shares at a placement price of HKD 14.50 per share. All conditions precedent have been met, and the delivery will be completed on October 16, 2025. The placement shares account for approximately 5.94% of the issued share capital before delivery and about 6.11% of the issued H shares, with a post-delivery proportion of approximately 5.61% and 5.76%

    Zhitong·
    HK
    01541
    +2.31%
    Zhitong·
    HK
    01541
    +2.31%

    Understanding the Market | IMMUNEONCO-B rises over 5% as Treg cell therapy attracts attention; the company is actively advancing the clinical development of TaiZesumab

    IMMUNEONCO-B's stock price rose more than 5% in the morning, reaching HKD 11.47, with a trading volume of HKD 40.4765 million. The company is actively advancing the clinical development of the next-generation CTLA-4 antibody, Tezspire, aiming to exert anti-tumor efficacy by eliminating regulatory T cells (Treg cells) in the tumor microenvironment. The research and development of this drug is closely related to the findings of Nobel Prize winners in the field of immune tolerance mechanisms

    Zhitong·
    HK
    01541
    +2.31%
    Zhitong·
    HK
    01541
    +2.31%
    © 2025 Longbridge｜Disclaimer